{
  "variant_id": {
    "Gene": "LRRK2",
    "Protein_Change": {
      "ref": "G",
      "alt": "S",
      "position": "2019"
    },
    "variant_string_id": "LRRK2 G2019S"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "LRRK2 kinase activity is a key pathogenic mechanism in Parkinson's disease (PD), and variants like G2019S and R1441C are associated with PD by altering kinase activity.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly links LRRK2 kinase activity to PD pathogenesis and demonstrates that G2019S and R1441C disrupt this activity."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study uses kinase activity assays (enzyme activity assays), which are standard in the field for evaluating LRRK2 function in PD.",
      "judgment": "Yes",
      "reasoning": "Kinase activity assays are widely accepted for studying LRRK2's role in PD, directly modeling the disease mechanism.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3a: Basic Controls and Replicates",
      "extracted_paper_info": "The study includes wild-type (normal) and mutant (abnormal) controls, and experiments are performed in triplicate.",
      "judgment": "Yes",
      "reasoning": "Both controls and replicates are explicitly described, meeting the criteria for proceeding to Step 3c.",
      "next_step_or_outcome": "Proceed to Step 3c"
    },
    {
      "step_name": "Step 3c: Variant Controls",
      "extracted_paper_info": "The study compares G2019S and R1441C variants to wild-type, but does not explicitly mention other variants as controls.",
      "judgment": "No",
      "reasoning": "While controls are included, the paper does not explicitly list other pathogenic or benign variants as controls for comparison.",
      "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
    },
    {
      "step_name": "Step 4a: Statistical Analyses",
      "extracted_paper_info": "The paper reports statistically significant changes in kinase activity (e.g., 'significantly increased' and 'significantly decreased') but does not provide OddsPath values.",
      "judgment": "No",
      "reasoning": "Statistical significance is implied, but no OddsPath values are reported, requiring further evaluation in Step 4b.",
      "next_step_or_outcome": "Proceed to Step 4b"
    },
    {
      "step_name": "Step 4b: No OddsPath Calculation",
      "extracted_paper_info": "The study examines only two variants (G2019S and R1441C) as part of the analysis.",
      "judgment": "10 or less",
      "reasoning": "The total number of controls (benign/pathogenic variants) across the study is â‰¤ 10, as only two variants are explicitly analyzed.",
      "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_supporting"
  },
  "overall_conclusion": "The G2019S variant shows statistically significant increased kinase activity compared to wild-type, directly disrupting LRRK2 function in PD. The assay is valid, but the limited number of controls (n=2 variants) results in PS3_supporting evidence strength."
}